BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

25 أغسطس 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

05 أغسطس 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

23 يوليو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

22 يوليو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

30 يونيو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

26 يونيو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

02 يونيو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

20 مايو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

19 مايو 2025 09:33:39 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 مايو 2025 13:01:00 بحسب Nasdaq GlobeNewswire

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

13 مايو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

12 مايو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

07 مايو 2025 04:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

29 أبريل 2025 13:01:00 بحسب Nasdaq GlobeNewswire

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28 أبريل 2025 02:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

22 أبريل 2025 04:30:36 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 أبريل 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

31 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

27 مارس 2025 04:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

24 مارس 2025 04:30:00 بحسب Nasdaq GlobeNewswire